Navigation Links


announces at Biology News

Wiley announces publication of Databasing the Brain

Understanding the structure, function, and development of the brain in health and disease represents one of the great scientific challenges of our time. The emerging field of neuroinformatics integrates neuroscience with informatics to create unique databases and analytical tools for the large variety of neuroscience data types, applying them to brain research and linking them with databases with...

Nonlinear Dynamics announces more details of its global partnership with PerkinElmer

Nonlinear Dynamics Ltd, a leading provider of bioinformatics solutions, today announced further details of its global OEM partnership with PerkinElmer, Inc. (NYSE: PKI), a leading provider of drug discovery, life science research and analytical solutions. As detailed in a press release issued last week, PerkinElmer will distribute Nonlinear's full range of 1D, 2D and array software. Howeve...

FDA Announces Series of Changes to the Class of Marketed Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

The Food and Drug Administration (FDA) today announced a series of important changes pertaining to the marketing of the non-steroidal anti-inflammatory class of drugs, including COX-2 selective and prescription and non-prescription (over-the-counter (OTC)) non-selective NSAID medications. A list of these products is available on the Internet at http://www.fda.gov/cder/drug/infopage/cox2/default.h...

Ariadne Genomics Announces the Release of PathwayStudio?Central, Client-Server Software for Biological Pathway Analysis

Ariadne Genomics, Inc. today announced the release of PathwayStudio?Central, client-server software for visualization and analysis of biological pathways and gene regulation networks for bio-medical research labs, biotechnology and pharmaceutical companies. PathwayStudio?Central is available for a free 20 day trial at www.ariadnegenomics.com. PathwayStudio?Central builds pathways from micr...

Neurologix announces positive results of gene therapy clinical trial in Parkinson's disease

Investigators report safety findings and statistically significant improvements in clinical measures of movement, PET Scans at 19th Annual Symposia on the Etiology, Pathogenesis and Treatment of Parkinson's Disease and Other Movement DisordersNeurologix's Phase I trial showed positive interim results in patients with Parkinson's disease. One year following treatment, patients exhibited a statist...

More>>

announces at Biology Products
announces at Biology Technology

RedPrairie announces RFID 360 compliance software

Waukesha, Wis. The first softwar...

APIs announces health care shift-bidding software

Hartford, Wis. APIs shift-bidding module is expected to be another way for hospitals to address what the Association of...

Merge eFilm announces rapid growth in first quarter

MILWAUKEE -- Merge Technologies Inc. announced Wednesday that its net sales are up 41 percent in first-quarter 2004, compared to first-quarter 2003. The Milwaukee-based company, which does business as RIS Logic's pro...

Firstlogic announces availability of mailroom technology

La Crosse, Wis, -- , a provider of information quality and postal automation solutions, announced Wednesday the general availability of the latest release of the firms directory retrieval system (DRS) software solution. DRS is designed for use on multi-line optical character recognition automation equipment. The solution enab...

Speaker announces business members of IT Task Force

Assembly Speaker Mike Huebsch, R-West Salem, and State Rep. Phil Montgomery, R-Green Bay, announced the following appointments: Tom Andreoli, CIO, <a href="http://www.schreiberfo...

More>>

announces at Medicine News

PM announces a new health care order for India

This year India’s Health care has been in constant limelight nationally as well as internationally. The effectiveness// of the healthcare system in India came to focus after the Tsunami took place in Chennai. This calamity rocked the City leaving thousands homeless, many orphaned and a rising risk of water born diseases. The Chennai government worked quickly and effectively with the peop...

Ramdoss Announces Introduction of RCH-II

Anbumani Ramdoss, the Union Minister for Health and Family Welfare, announced that the Government would be spending Rs. 40,000 crore on the second phase of the Reproductive and Child Health Programme called RCH-II.// Mr. Ramdoss announced this package at the 49th All India Congress of Obstetrics and Gynaecology in Kochi yesterday. He said that the challenge in front of the health sector...

Britain Announces Third Transfusion Related 'Mad Cow' Case

The Health Protection Agency (HPA) has reported a third case of variant-CJD (a brain disease that represents human form of mad cow disease) in Britain. The patient is said to have contracted the disease from a blood transfusion // that had taken place 8 years ago. The donor who had developed symptoms of the disease much earlier, 20 months following the transfusion is under strict medi...

Tibet Announces the Dalai Lama’s Tour of South Americ

Five South American countries are on the travel itinerary of Tibetan spiritual leader the Dalai Lama from April 26// to May 12. The cities he will go to are Sao Paulo, the largest city of Brazil, Buenos Aires, the Argentine capital, Santiago (Chile), Lima (Peru) and Bogota (Colombia). In Brazil, the Dalai Lama will also visit Zu Lai, the biggest Chinese Mahayana Buddhist templ...

NHS announces further Cost cutting Measures

Debt- ridden NHS hospitals have announced further job cuts with three NHS hospitals in Worcestershire being the latest hit. The affected hospitals are the Worcestershire Royal Hospital// in Worcester, the Alexandra Hospital in Redditch, and Kidderminster Hospital. The hospitals which were run by the Worcestershire Acute Hospitals NHS Trust, will decrease approximately 15 percent of th...

More>>

announces at Medicine Products
announces at Medicine Technology

Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial

LONDON, 12 July 2007 - Cancer drug developer Antisoma plc(LSE: ASM, US OTC: ATSMY) today announces new data from its phaseII trial of ASA404 in recurrent, platinum-sensitive ovarian cancer.This trial compares patients receiving ASA404 plus chemotherapy(n=37) with patients receiving chemotherapy alone (n=38). The mainfindings are as follows: * There was no advantage in median time t...

Sygnis Pharma AG announces date for presentation of clinical results

HEIDELBERG, Germany, 11 July 2007 – On 23 July SYGNIS PharmaAG will present the results of the clinical phase IIa study forAX200 (AXIS-study). AX200, a compound for the treatment of stroke, is the mostadvanced drug candidate in SYGNIS’ product pipeline. Theprimary aim of the study is to show safety and tolerability ofAX200 in acute stroke patients. The results of the AXIS-stud...

Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis

HORSHAM, Pa.--(BUSINESS WIRE)--Jul 11, 2007 - Neose Technologies,Inc. (Nasdaq GM:NTEC) today announced that two poster presentationswere presented with its collaborative partner, Novo Nordisk A/S,relating to GlycoPEGylated recombinant Factor VIIa at the XXIstCongress of the International Society on Thrombosis and Haemostasisin Geneva, Switzerland. The data presented demonstrates thatGlycoPE...

Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis

LEVERKUSEN, Germany - Biofrontera AG (DSE: B8F) announces todaythat it has received very positive results in the dose finding partof its phase IIb/III clinical trial started in autumn 2006. BF-200ALA, a gel that combines the active substance 5-aminolevulinic acid(ALA) with the nanoemulsion BF-200, was strongly and significantlysuperior to placebo in the treatment of actinic keratosis. BF-...

YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial

- Company Announces Lead Investigator for U.S. Trial - MISSISSAUGA, ON, July 11, 2007 /PRNewswire-FirstCall/ - YMBioSciences Inc. , an oncology company that identifies, developsand commercializes differentiated products for patients worldwide,today announced results of secondary endpoint data from its 99patient, randomized, placebo-controlled, multi-center Phase IIbtrial (DLXLEF-AP4) with...

More>>

Other TagsConnectConnectConnectConnectInternalInternalSpinalSpinalSpinalSpinalAutisticSurvivorsBrazil
(Date:11/18/2008)...ury-free this Holiday Season , , ROSEMONT, ...d travelers have a saying -- " Pack your bags, the...ost of us bring much more than we need on our trip..., especially, since so many airline providers are ...owever, if you are one of those people who cannot ...
(Date:11/18/2008)...isease effect in postmenopausal women, study says ... Scientists believe they have found out why diet a...er after she,s past menopause, a new study says. ...tin found that cutting calories and exercise affec...rgy balance with cell growth and can contribute to...
(Date:11/18/2008)... oil during gestation and lactation , ,...mothers consumed canola oil during pregnancy and b... cancer than those whose mothers consumed corn oil...ant and lactating mice a diet high in either corn ...ated fats, or canola oil, which contains only 20 p...
(Date:11/18/2008)...elected Emory University for a $2.5 million, five-...ists whose expertise in research and teaching will...The Emory program is one of three new BWF programs...m Unifying Population and Laboratory Based Science...niversity of California, Los Angeles (metabolic di...
Breaking Medicine News(10 mins):Health News:Lug Your Luggage Safely 2Health News:Lug Your Luggage Safely 3Health News:Diet, Exercise May Modify Breast Cancer Risks 2Health News:Canola Oil Consumed During Pregnancy Lowers Breast Cancer Risk for Offspring 2Health News:Burroughs Wellcome Fund award creates new Ph.D. path linking laboratory and population sciences 2Health News:Burroughs Wellcome Fund award creates new Ph.D. path linking laboratory and population sciences 3
(Date:11/18/2008)...abama at Birmingham (UAB) Center for Education and...illion federal grant to study the risks and benefi... These are genetically engineered therapies that t...atoid arthritis, Crohn,s disease, psoriasis and ot... the UAB CERTs to pinpoint which biologics have po...
(Date:11/18/2008)...lay a crucial role in sustaining the biodiversity ...ntly held workshop organised by the European Scien...nt clues for protecting Europe,s rivers against a ...ate change, which are tampering with existing ecos...al forces acting upon them. , Both aquatic plan...
(Date:11/18/2008)...FG, German Research Foundation) is intensifying th...At its autumn meeting in Bonn the Grants Committee...stablishment of 13 additional Research Training Gr...ng Groups. These enable doctoral researchers to co... particularly pleased about the first Internationa...
(Date:11/17/2008)... research team has found a new gene associated wit...gene mutation was specific to a rare form of epile...s for overall epilepsy treatment. , The findings...m six different countries, appear in the Nov. 7 is..., In epilepsy, nerve cells in the brain signal ab...
Breaking Biology News(10 mins):Musculoskeletal center wins $2.2 million for drug safety 2Alpine rivers hold important clues for preserving biodiversity and coping with climate change 2Alpine rivers hold important clues for preserving biodiversity and coping with climate change 3National and international doctoral training 2National and international doctoral training 3National and international doctoral training 4National and international doctoral training 5National and international doctoral training 6National and international doctoral training 7International team discovers gene associated with epilepsy 2Nastech to Establish Subsidiary MDRNA Inc as an Independent Company to Focus on the Development of RNA Based Therapeutics 6265 1Nastech to Establish Subsidiary MDRNA Inc as an Independent Company to Focus on the Development of RNA Based Therapeutics 6265 2Nastech to Establish Subsidiary MDRNA Inc as an Independent Company to Focus on the Development of RNA Based Therapeutics 6265 3Nastech to Establish Subsidiary MDRNA Inc as an Independent Company to Focus on the Development of RNA Based Therapeutics 6265 4Nastech Pharmaceutical Company Initiates Plan for Corporate Restructuring and Will Concentrate on Phase 2 Clinical Programs 6263 1Nastech Pharmaceutical Company Initiates Plan for Corporate Restructuring and Will Concentrate on Phase 2 Clinical Programs 6263 2Nastech Pharmaceutical Company Initiates Plan for Corporate Restructuring and Will Concentrate on Phase 2 Clinical Programs 6263 3Nastech Pharmaceutical Company Initiates Plan for Corporate Restructuring and Will Concentrate on Phase 2 Clinical Programs 6263 4Roche Confirms Commencement of Due Diligence with Ventana 6261 1Roche Confirms Commencement of Due Diligence with Ventana 6261 2Roche Confirms Commencement of Due Diligence with Ventana 6261 3Roche Confirms Commencement of Due Diligence with Ventana 6261 4Sound medicine at Acoustics Meeting 6259 1Sound medicine at Acoustics Meeting 6259 2Sound medicine at Acoustics Meeting 6259 3Sound medicine at Acoustics Meeting 6259 4Sound medicine at Acoustics Meeting 6259 5Sound medicine at Acoustics Meeting 6259 6Sound medicine at Acoustics Meeting 6259 7Sound medicine at Acoustics Meeting 6259 8
Other Contentspostpostpostpostpostpostpostpostpredationpredationpreprepreprimaseextensionextensionextensionextensionextensionextensionextensionextensionextensionstreakstreak